At TAMC Medical Clinic in Tel Aviv, a scientific breakthrough is making waves in how breast cancer is managed – a disease considered one of the most common and life-threatening cancers among women worldwide. A new technology now enables, for the first time, the prevention of disease progression using a unique blood test, performed as part of personalized monitoring of the patient’s condition. The clinical study involved an innovative medication called Camizestrant, developed by AstraZeneca.
How does it work?
The technology is based on analyzing blood samples to detect molecular markers (such as ctDNA and CTCs) that are released into the bloodstream from cancer cells. Analyzing these data provides an accurate and up-to-date picture of the disease — without the need for invasive procedures or frequent imaging. When changes are identified, treatment can be adjusted immediately, and in some cases, disease progression or recurrence can even be prevented.
TAMC: Personalized Oncology – Here and Now
At TAMC, we believe that modern oncology must be personalized. The clinic’s team of specialists incorporates these innovative blood tests into treatment protocols for women with advanced or metastatic breast cancer, adapting biological or immunotherapy treatments in real-time based on the results.
Why is it important?
In the past, oncology treatments were adjusted based on periodic imaging or clinical response. Today, with smart blood tests, it’s possible to detect changes before they manifest physically or are visible on imaging – and intervene earlier.
Available for Patients from Abroad
As a leading private oncology center in Israel, TAMC offers this service to international patients as part of its private medicine program. The clinic provides access to top doctors in Tel Aviv, participation in clinical trials, and personal support in English, Russian, French, or Arabic.
